Peter George

Peter has built a career spanning healthcare, life sciences, entrepreneurship and philanthropy, having qualified in Pathology, with a Masters in both Clinical Biochemistry and Immunology and an Executive MBA from Kellogg School of Management, Northwestern University Chicago.

In 2017 he stepped down from running Clinigen plc to found Enigma Holdings, an investment company that specialises in health, wellbeing, sport, learning, community and social housing, and XPG Ltd, an investment company focused on property. 

Clinigen Group plc is a company Peter started in 2010 as a global specialty pharmaceuticals and pharma services business and floated in 2012; by 2016 it had a c.£1bn+ market cap, being one of the most successful floats on the AIM stock market.

Prior to Clinigen Peter led the £67m management buy-out of Penn Pharmaceuticals, which was crowned “the PE deal of the year 2007”, where he was also named European Private Equity CEO of the year 2010. Whilst leading Clinigen numerous awards were gained for the company; No.1 Sunday Times Fast Track profit 100 (2011), Bionow Investment deal of the year(2012), M&A Awards IPO of the year & AIM Awards Best Newcomer (2013), European Business Awards – Business of TO €26m-€150m (2014) and LSE Top 100 inspiring British companies (2015). And for Peter personally he was named European Mediscience CEO of the year in 2014 and Entrepreneur of the year at the 2016 AIM Awards.

Peter is currently Chair of Enigma Holdings Group Ltd, AI Sight Ltd and Rent Plus UK Ltd, as well as being a partner in Mount Cooke Properties Ltd, a Charity promoting outdoors for all.  He also sits on Cancer Research UK's Global Campaign Leadership Committee for the More Research, Less Cancer campaign.  Peter previously Chaired Crown Commercial Services, the UK Governments’ procurement services.

As Chair of the Development Committee, Peter will help guide the institute’s fundraising strategy and build the philanthropic support needed to power its next phase of development, backing pioneering discovery science and the Crick’s long-term ambitions.